Abstracts Archive - Page 2132 of 2425 - ACR Meeting Abstracts

Abstract Number: 1801 • 2013 ACR/ARHP Annual Meeting
Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy
Désiréé van der Heijde¹, Walter P. Maksymowych², Joachim Sieper³, Robert Lambert⁴, Matthew A. Brown⁵, Suchitrita S. Rathmann⁶, Jaclyn K. Anderson⁶ and Aileen L. Pangan⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Radiology, University of Alberta Hospital, Edmonton, AB, Canada, ⁵Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…
Abstract Number: 1802 • 2013 ACR/ARHP Annual Meeting
A Major Clinical Response To Anti-Tumor Necrosis Factor Agents Is Associated With a Reduced Development Of Fatty Changes In The Spine Of Patients With Ankylosing Spondylitis
Xenofon Baraliakos¹, Frank Heldmann², Joachim Listing³, Johanna Callhoff³ and Jürgen Braun², ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Fatty changes (FC) on T1-weighted magnetic resonance images (MRI) have been described in the spine of patients with ankylosing spondylitis (AS). Such lesions were…
Abstract Number: 1803 • 2013 ACR/ARHP Annual Meeting
Is Site Of Back Pain Related To Location Of Inflammatory and Structural Lesions On MRI In Patients With Chronic Back Pain?
Manouk de Hooge¹, Rosaline van den Berg², Floris van Gaalen², Victoria Navarro-Compán², Monique Reijnierse³, Karen Fagerli⁴, Maureen C. Turina⁵, Maikel van Oosterhout⁶, Roberta Ramonda⁷, Tom Huizinga² and Désirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, GHZ Hospital, Gouda, Netherlands, ⁷Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: Pain has found to be related to inflammatory lesions in thoracic, lumbar and sacroiliac joints (SIJ) sites and to structural lesions in the SIJ…
Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting
Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Ananta Subedi¹, Hong Fang² and Michelle Petri², ¹Good Samaritan Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…
Abstract Number: 1806 • 2013 ACR/ARHP Annual Meeting
Association Between Hydroxychloroquine Exposure and Incidence Of Diabetes Mellitus In Systemic Lupus Erythematosus
Michelle Petri¹ and Laurence S. Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Diabetes mellitus is one of the SLICC/ACR Damage Index items and a recognized risk factor for cardiovascular disease and renal failure. In rheumatoid arthritis,…
Abstract Number: 1807 • 2013 ACR/ARHP Annual Meeting
Do We Know How and When To Taper and Stop In Immunosuppressants In Lupus Patients?
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: After achieving low disease activity or remission, immunosuppressant therapies might be stopped in lupus patients, but information on whether and how this should be…
Abstract Number: 1768 • 2013 ACR/ARHP Annual Meeting
Value Of Arthroscopic Partial Meniscectomy In Treatment Of Symptomatic Patients With Meniscal Tears and Knee Osteoarthritis: Is More Research Warranted?
Elena Losina¹, A. David Paltiel², Elizabeth Dervan¹, Yan Dong¹, Kurt P. Spindler³, Lisa A. Mandl⁴, Morgan Jones⁵, John Wright⁶ and Jeffrey N. Katz⁷, ¹Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Yale School of Public Health, New Haven, CT, ³Vanderbilt University, Nashville, TN, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, ⁶Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Arthroscopic partial meniscectomy (APM) is often offered to patients with symptomatic meniscal tear (MT). Recent trials in symptomatic patients with MT and knee OA…
Abstract Number: 1769 • 2013 ACR/ARHP Annual Meeting
Direct and Indirect Costs For Patients With Systemic Lupus Erythematosus In National Cohorts In Sweden
Andreas Jönsen¹, Anders A. Bengtsson¹, Christine Bengtsson², Iva Gunnarsson³, Johanna Gustafsson³, Frida Hjalte⁴, Dag Leonard⁵, Susanne Pettersson³, Solbritt Rantapää Dahlqvist⁶, Lars Rönnblom⁷, Christopher Sjöwall⁸, Katarina Steen Carlsson⁹, Elisabet Svenungsson¹⁰, Minna Willim¹¹ and Ola Nived¹², ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dpt of Public Health and Clinical Medicine, Umeå University, Rheumatology, Umeå, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴The Swedish Institute for Health Economics,, Health Economy, Lund, Sweden, ⁵Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁶Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ⁸Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁹The Swedish Institute of Health Economics, Health Economy, Lund, Sweden, ¹⁰Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ¹¹Department of Clinical Sciences Malmö, Section of Rheumatology, Lund University, Malmö, Sweden, ¹²Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden
Background/Purpose: To study direct and indirect costs for patients with Systemic Lupus Erythematosus (SLE) ín five defined cohorts with nationwide spread in Sweden, and to…
Abstract Number: 1770 • 2013 ACR/ARHP Annual Meeting
All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System
Jessica Widdifield^1,2, J. Michael Paterson¹, Sasha Bernatsky³, Bindee Kuriya⁴, J. Carter Thorne⁵, Simon Hollands¹ and Claire Bombardier⁶, ¹Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Studies evaluating trends in rheumatoid arthritis (RA) mortality over time have produced inconsistent results. Our aim was to estimate all-cause mortality in RA between…
Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Malte Wolff¹, Zheng-Yi Zhou², James Signorovitch², James W. Shaw³ and Arijit Ganguli³, ¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…
Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
P.H.P. de Jong¹, A.E.a.M. Weel², J.J. Luime³, P.J. Barendregt², A.H. Gerards⁴, P.A. van der Lubbe⁴, M.H. de Jager⁵, P.B. de Sonnaville⁶, D. van Zeben⁷, B.A. Grillet⁸ and J.M.W. Hazes³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁷Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁸Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…
Abstract Number: 1773 • 2013 ACR/ARHP Annual Meeting
The Contribution Of Environmental Factors To Familial Risk Of Rheumatoid Arthritis By Serologic Phenotypes Among Women In a Longitudinal Cohort Study
Jeffrey A. Sparks¹, Chia-Yen Chen², Linda T. Hiraki³, Susan Malspeis⁴, Karen H. Costenbader⁴ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Familial risk of RA is composed of shared genetic and environmental factors. Previous studies exploring familial risk of RA have not incorporated environmental factors…
Abstract Number: 1774 • 2013 ACR/ARHP Annual Meeting
Sepsis Is The Leading Cause Of Hospital Mortality In Dermatomyositis/Polymyositis: Data From a Population-Based Study
Sara Murray¹, Laura Trupin¹, Chris Tonner¹, Matthew Cascino¹, Gabriela Schmajuk¹, Mary Margaretten², Jennifer Barton¹, Patricia P. Katz¹, Edward H. Yelin³ and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, UC San Francisco, San Francisco, CA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are debilitating inflammatory myopathies with five-year mortality rates estimated to be 33%. However, the leading causes of inpatient…
Abstract Number: 1775 • 2013 ACR/ARHP Annual Meeting
Use Of “Computer-Aided Lung Informatics For Pathology Evaluation and Rating” Software In High-Resolution Computed Tomography In Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease
Katelynn Wilton¹, Brian Bartholmai², Sanjay Kalra³, Cynthia S. Crowson⁴, Helen Khun⁴ and Floranne C. Ernste⁵, ¹Mayo Clinic College of Medicine, Rochester, MN, ²Thoracic Radiology, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are associated with interstitial lung disease (ILD), characterized by parenchymal abnormalities on high-resolution computed tomography (HRCT). We determined the…
Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Rohit Aggarwal¹, Chester V. Oddis², Erich R Wilkerson³, Diane Koontz⁴, Ilinca D. Metes⁵, Ann M. Reed⁶, Dana P. Ascherman⁷ and Marc C. Levesque⁸, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].